The Cost-Effectiveness of Daclizumab Beta Vs Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis Patients With Inadequate Response To Prior Treatment In Scotland
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.1950
https://www.valueinhealthjournal.com/article/S1098-3015(17)32284-2/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1772
First Page :
A723
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32284-2&doi=10.1016/j.jval.2017.08.1950